Allergy

11
Pipeline Programs
8
Companies
16
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
4
0
1
1
5
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Stallergenes Greer
Stallergenes GreerFrance - Antony
7 programs
1
1
4
300 IRPhase 31 trial
300 IR grass pollen allergen extract tabletPhase 31 trial
Skin prick-testPhase 31 trial
StaloralPhase 31 trial
100 IR grass pollen allergen extract tabletPhase 2/31 trial
+2 more programs
Active Trials
NCT02295969Completed307Est. Jul 2017
NCT00410930Terminated160Est. Nov 2005
NCT00367640Completed628Est. Sep 2005
+4 more trials
Abbott
AbbottABBOTT PARK, IL
1 program
1
MitizaxPhase 31 trial
Active Trials
NCT02596321Completed112Est. Jun 2016
J&
Johnson & JohnsonNEW BRUNSWICK, NJ
1 program
1
CetirizinePhase 14 trials
Active Trials
NCT03772158Completed40Est. Feb 2019
NCT01322282Completed36Est. Mar 2011
NCT01068223Completed24Est. May 2010
+1 more trials
UP
UCB PharmaBelgium - Brussels
1 program
1
LevocetirizinePhase 11 trial
Active Trials
NCT00521170CompletedEst. Jan 2005
Sandoz
SandozAustria - Kundl
1 program
1
Loratadine 10 mg Tablets Under Fasting ConditionsPhase 11 trial
Active Trials
NCT00946608CompletedEst. Aug 2005
Regeneron
RegeneronTARRYTOWN, NY
1 program
1
REGN1908-1909Phase 11 trial
Active Trials
NCT02127801Completed74Est. Dec 2015
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
Understanding Allergies and Sensitizations in Healthy and Allergic IndividualsN/A1 trial
Active Trials
NCT04828603RecruitingEst. Dec 2028

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Johnson & JohnsonCetirizine
AbbottMitizax
Stallergenes GreerSkin prick-test
Stallergenes GreerStaloral
Stallergenes Greer300 IR grass pollen allergen extract tablet
Stallergenes Greer300 IR
Stallergenes Greer100 IR grass pollen allergen extract tablet
Stallergenes GreerSubcutaneous immunotherapy - Recombinant birch pollen
Johnson & JohnsonCetirizine
RegeneronREGN1908-1909
Johnson & JohnsonCetirizine
Johnson & JohnsonCetirizine
SandozLoratadine 10 mg Tablets Under Fasting Conditions
UCB PharmaLevocetirizine
Stallergenes GreerOralair

Showing 15 of 16 trials with date data

Clinical Trials (16)

Total enrollment: 3,783 patients across 16 trials

Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi-Center Study of the Efficacy and Safety of Cetirizine HCl Syrup vs. Loratadine Syrup vs. Placebo in Treatment of Children With Seasonal Allergic Rhinitis (SAR)

Start: Mar 2001Est. completion: Jul 2001683 patients
Phase 4Completed

A Study Investigating the Immunologic Effects and Safety of 60-day Treatment of the ALK HDM Tablets in Adult Subjects With HDM-Induced Allergic Rhinitis and/or Atopic Asthma

Start: Oct 2015Est. completion: Jun 2016112 patients
Phase 3Completed

Sensitivity and Specificity of 3 Solutions of Allergen Extract for Diagnosis by Skin Prick Testing

Start: Dec 2010Est. completion: Feb 2012324 patients
Phase 3Completed

A Phase III Study to Assess Efficacy and Safety of STALORAL® 300 IR Sublingual Immunotherapy (SLIT) in Asthmatic Patients Allergic to House-dust Mites

Start: Oct 2007Est. completion: Jul 2009484 patients
Phase 3Completed
NCT00409409Stallergenes Greer300 IR grass pollen allergen extract tablet

Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Children Suffering From Grass Pollen Rhinoconjunctivitis

Start: Dec 2006Est. completion: Sep 2007278 patients
Phase 3Completed

Phase III Study to Assess the Long Term Efficacy, Carry-over Effect and Safety of 300 IR Sublingual Immunotherapy Tablets

Start: Dec 2006Est. completion: Sep 2011633 patients
Phase 3Completed
NCT00367640Stallergenes Greer100 IR grass pollen allergen extract tablet

Safety and Efficacy of Sublingual Immunotherapy (SLIT) Tablets in Grass Pollen Rhinoconjunctivitis

Start: Nov 2004Est. completion: Sep 2005628 patients
Phase 2/3Completed
NCT00410930Stallergenes GreerSubcutaneous immunotherapy - Recombinant birch pollen

Efficacy and Safety of Subcutaneous Immunotherapy in Birch Pollen Allergic Patients

Start: Nov 2002Est. completion: Nov 2005160 patients
Phase 2Terminated

Cetirizine Chewable Bioequivalence and Food Effect Study

Start: Dec 2018Est. completion: Feb 201940 patients
Phase 1Completed

Single Ascending-dose Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Participants

Start: Oct 2014Est. completion: Dec 201574 patients
Phase 1Completed

To Test Bioequivalence Between Two Tablet Formulations in the Treatment of Allergy

Start: Feb 2011Est. completion: Mar 201136 patients
Phase 1Completed

A Study To Investigate The Effect of JNJ-39758979 on Histamine Induced Itch in Healthy Male Volunteers

Start: Feb 2010Est. completion: May 201024 patients
Phase 1Completed
NCT00946608SandozLoratadine 10 mg Tablets Under Fasting Conditions

To Demonstrate the Relative Bioavailability Study of Loratadine 10 mg Tablets

Start: Jun 2005Est. completion: Aug 2005
Phase 1Completed
NCT00521170UCB PharmaLevocetirizine

Wheal and Flare Reaction During 24 Hours in Allergic Volunteers.

Start: Nov 2004Est. completion: Jan 2005
Phase 1Completed

Observational Study of Oralair® in Children 5-9 Years With Grass-pollen-induced Allergic Rhinitis With/Without Conjunctivitis

Start: Dec 2014Est. completion: Jul 2017307 patients
N/ACompleted
NCT04828603Allergy TherapeuticsUnderstanding Allergies and Sensitizations in Healthy and Allergic Individuals

Understanding Allergies and Sensitizations in Healthy and Allergic Individuals

Start: Oct 2007Est. completion: Dec 2028
N/ARecruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

5 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 3,783 patients
8 companies competing in this space